Metalcaptase® 150 mg

Active substance:

Penicillamine

ATC-Code :

M01CC01

Pharmaceutical form:

enteric coated tablet

Therapeutic indications:

Morbus Wilson
Lead, mercury, copper and zinc poisoning
Rheumatoid arthritis
Cystinuria with detected cysteine stones when recurrence of stones cannot be prevented by other methods (methionine-free diet, hyperhydration, alkalisation of Urine) as well as in cases of advanced cysteine stone disorders invólving Special risks (e.g. after nephrectomy).
There is some evidence that scleroderma may respond to treatment with Metalcaptase 150 mg.

PDF-Download summary of product characteristics

PDF-Download package leaflet

11.05.2016 | Category: » Pharma

Wilson JP et al. 2015; Decorporation of systemically distributed americium by a novel orally administered diethylenetriaminepentaacetic Acid (DTPA) formulation in beagle dogs; Health Phys. 108(3):308-18

Study design: Beagle dogs received various doses of NanoDTPATM capsules to decorporate administered 241Americium (241Am). Efficacy of NanoDTPATM was compared to intravenously … » More

11.05.2016 | Category: » Pharma

Shankar GN et al. 2014; Evaluating the toxicity of novel Zn-DTPA tablet formulation in dogs and rats; Drug Dev. Res. 75(1):37-46

Study design: Beagle dogs were treated with increasing doses of trisodium zinc pentetate (Zn-DTPA) in a novel oral solid tablet form for seven days to determine its toxicity … » More

11.05.2016 | Category: » Vitamine

Schwartz JB et al. 2016; Response of vitamin D concentration to vitamin D₃ administration in older adults without sun exposure: A randomized double-blind trial; J. Am. Geriatr. Soc. 64(1):65-72

Study design: Randomized double-blind investigation to evaluate the 25 OHD levels in elderly nursing home residents after 16 weeks when 800, 2 000 or 4 000 IU/day or 50 000 … » More

11.05.2016 | Category: » Vitamine

Välimäki VV et al. 2016; How well are the optimal serum 25OHD concentrations reached in high-dose intermittent vitamin D therapy? A placebo-controlled study on comparison between 100 000 IU and 200 000 IU of oral D₃ every 3 months in elderly women; Clin. Endocrinol. 84(6):837-44

Study design: Elderly women received 100 000 or 200 000 IU of vitamin D3 or placebo orally every 3 months plus 1 g of calcium daily over one year to test intermittent … » More

HEYL

Chemisch-pharmazeutische Fabrik GmbH & Co. KG

Metalcaptase® 150 mg

Login for medical expert groups

Please enter your Heyl password

Request login information